In this issue:
Permeability of the BBB predicts NEDA after natalizumab or fingolimod in RRMS
Progression of regional grey matter atrophy in MS
Ofatumumab in patients with RRMS
PML after fingolimod treatment
Increased incidence of MS over six decades in Denmark
Alemtuzumab treatment and risk of acute acalculous cholecystitis
MRZR and intrathecal IgG synthesis to differentiate between PCNSL and MS
Elevated anti-JCV indexes in Japanese MS patients treated with fingolimod
Cladribine treatment and depletion of memory B cells
Characterisation of annual disease progression of MS patients
Please login below to download this issue (PDF)